SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sanofi India strengthens on reporting 10% rise in Q1 net profit

02 May 2013 Evaluate

Sanofi India is currently trading at Rs. 2599.25, up by 44.40 points or 1.74% from its previous closing of Rs. 2554.85 on the BSE.

The scrip opened at Rs. 2599.25 and has touched a high and low of Rs. 2599.25 and Rs. 2599.25 respectively.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 2899.00 on 10-Apr-2013 and a 52 week low of Rs. 2002.10 on 07-Jun-2012.

Last one week high and low of the scrip stood at Rs. 2649.00 and Rs. 2500.00 respectively. The current market cap of the company is Rs. 0.00 crore.

The promoters holding in the company stood at 60.40% while Institutions and Non-Institutions held 26.74% and 12.86% respectively.

Sanofi India has reported results for first quarter ended March 31, 2013.

The company has reported 10.47% rise in its net profit of Rs 44.30 crore for the quarter ended March 31, 2013 as compared to Rs 40.10 crore for the same quarter in the previous year. Total income from operation of the company has increased by 13.35% at Rs 388.10 crore for quarter under review as compared to Rs 342.40 crore for the quarter ended March 31, 2012.

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.

Sanofi India Share Price

3500.00 -87.20 (-2.43%)
22-Apr-2026 12:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1660.50
Dr. Reddys Lab 1220.55
Cipla 1233.50
Zydus Lifesciences 931.50
Lupin 2310.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×